US equities |
MU $795.41 ▲+0.02% SNDK $1,037.40 ▲+0.00% NVDA $200.13 ▲+0.00% AMD $488.78 ▲+0.00% SKHY $143.07 ▲+0.00% INTC $58.27 ▲+0.00% TSLA $385.19 ▲+0.00% SPCX $135.92 ▲+0.00%
FinancialContent

Articles published by AdvanCell

News headline image
AdvanCell Strengthens Leadership with Appointment of Andy Porter as Chief People Officer and Martin Huber, M.D., to its Board of Directors
From AdvanCell
Via Business Wire
News headline image
AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data
From AdvanCell
Via Business Wire
News headline image
AdvanCell Appoints Sean Cassidy as Chief Financial Officer
From AdvanCell
Via Business Wire
News headline image
AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026
From AdvanCell
Via Business Wire
News headline image
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
From AdvanCell
Via Business Wire
News headline image
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
From AdvanCell
Via Business Wire
News headline image
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
From AdvanCell
Via Business Wire
News headline image
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
From AdvanCell
Via Business Wire
News headline image
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
From AdvanCell
Via Business Wire
News headline image
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
From AdvanCell
Via Business Wire
News headline image
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
From AdvanCell
Via Business Wire
News headline image
AdvanCell to participate in Jefferies Global Healthcare Conference in London
From AdvanCell
Via Business Wire
News headline image
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
From AdvanCell
Via Business Wire
News headline image
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
From AdvanCell
Via GlobeNewswire
News headline image
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
From AdvanCell
Via GlobeNewswire
News headline image
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025
From AdvanCell
Via Business Wire
News headline image
AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
From AdvanCell
Via Business Wire
News headline image
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
From AdvanCell
Via Business Wire
News headline image
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
From AdvanCell
Via Business Wire
News headline image
AdvanCell Expands Leadership Team with the Appointment of Christopher Horvath, MS MBA, as Chief Commercial Officer & Chief Operating Officer and Gary Li, PhD, as Chief Strategy Officer
From AdvanCell
Via Business Wire
News headline image
AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer
From AdvanCell
Via Business Wire
News headline image
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer
From AdvanCell
Via Business Wire
News headline image
AdvanCell Closes A$18M Series B Funding Led by Morningside
From AdvanCell
Via Business Wire